UroGen Pharma Ltd. (URGN) › Capital ExpendituresUroGen Pharma Ltd. (URGN) — Capital ExpendituresAnnual figures by period end, from SEC filings.2015-12-31: $301.0K2016-12-31: $695.0K2017-12-31: $271.0K2018-12-31: $560.0K2019-12-31: $325.0K2020-12-31: $1.22M2021-12-31: $752.0K2022-12-31: $254.0K2023-12-31: $194.0K2024-12-31: $295.0K2025-12-31: $289.0K$289.0K2015-12-31Capital Expenditures (USD)2025-12-31Period endedCapital ExpendituresChange YoYSource filing2025-12-31$289.0K-2.0%2026-03-02From 2025-01-012024-12-31$295.0K+52.1%2026-03-02From 2024-01-012023-12-31$194.0K-23.6%2025-03-10From 2023-01-012022-12-31$254.0K-66.2%2024-03-14From 2022-01-012021-12-31$752.0K-38.1%2023-03-24From 2021-01-012020-12-31$1.22M+273.8%2022-03-21From 2020-01-012019-12-31$325.0K-42.0%2021-03-18From 2019-01-012018-12-31$560.0K+106.6%2020-03-02From 2018-01-012017-12-31$271.0K-61.0%2020-03-02From 2017-01-012016-12-31$695.0K+130.9%2019-02-28From 2016-01-012015-12-31$301.0K—2018-03-15From 2015-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)